Get started
Keyword

BRCA mutations

Description: Genetic variants in BRCA1 or BRCA2 that can impair DNA repair and are associated with inherited cancer susceptibility.
Wikidata ID: wiki/Q4836333
OpenAlex ID: keywords/brca-mutations
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 · Giampaolo Bianchini, Justin M. Balko, et al. · Nature Reviews Clinical Oncology · 3,055
Breast cancer
2019 · Nadia Harbeck, Frédérique Penault-Llorca, et al. · Nature Reviews Disease Primers · 2,998
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
2019 · Antonio González-Martín, Bhavana Pothuri, et al. · New England Journal of Medicine · 2,267
PDF
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
2019 · Isabelle Ray-Coquard, Patricia Pautier, et al. · New England Journal of Medicine · 2,063
PDF
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 · Jonathan Ledermann, Philipp Harter, et al. · New England Journal of Medicine · 1,883
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Robert L Coleman, Amit M Oza, et al. · The Lancet · 1,695
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
2016 · Elizabeth M Swisher, Kevin K Lin, et al. · The Lancet Oncology · 1,195
State-of-the-art strategies for targeting the DNA damage response in cancer
2018 · Patrick G. Pilié, Chad Tang, et al. · Nature Reviews Clinical Oncology · 1,175
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
2016 · Melinda L. Telli, Kirsten M. Timms, et al. · Clinical Cancer Research · 1,130
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
2019 · Robert L. Coleman, Gini F. Fleming, et al. · New England Journal of Medicine · 916
PDF
The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome
2006 · Fabiola Medeiros, Michael G Muto, et al. · The American Journal of Surgical Pathology · 916
Treatment of epithelial ovarian cancer
2020 · Lindsay Kuroki, Saketh R Guntupalli · BMJ · 881
PDF
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
2020 · Maddison Rose, Joshua T. Burgess, et al. · Frontiers in Cell and Developmental Biology · 720
PDF
PARP and PARG inhibitors in cancer treatment
2020 · Dea Slade · Genes & Development · 668
PDF
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
2012 · Nicolai J. Birkbak, Zhigang C. Wang, et al. · Cancer Discovery · 662
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
2016 · Jessica S. Brown, Brent O'Carrigan, et al. · Cancer Discovery · 618
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
2018 · Jianfeng Shen, Wei Zhao, et al. · Cancer Research · 593
PDF
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014 · Joyce F Liu, William T Barry, et al. · The Lancet Oncology · 585
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
2019 · Kathleen N Moore, Angeles Alvarez Secord, et al. · The Lancet Oncology · 535
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
2020 · Kwang‑Ai Won, Charles Spruck · International Journal of Oncology · 530
PDF
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
2017 · Matthew B. Yurgelun, Matthew H. Kulke, et al. · Journal of Clinical Oncology · 524
An overview of prognostic factors for long-term survivors of breast cancer
2007 · Isabelle Soerjomataram, Marieke W. J. Louwman, et al. · Breast Cancer Research and Treatment · 513
PDF
The distal fallopian tube: a new model for pelvic serous carcinogenesis
2007 · Christopher P Crum, Ronny Drapkin, et al. · Current Opinion in Obstetrics & Gynecology · 512
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
2021 · Mariana Paes Dias, Sarah C. Moser, et al. · Nature Reviews Clinical Oncology · 508
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
2020 · Nadine M. Tung, Mark E. Robson, et al. · Journal of Clinical Oncology · 508
PDF
Works count: 6,336
Citation count: 108,500
Year
Topic
Type